Chris H. Takimoto, M.D., Ph.D.
Chief Medical Officer, Forty Seven, Inc.
After training in chemistry at Stanford University, Dr. Takimoto received his Ph.D. in pharmacology and his M.D. from Yale University. He completed fellowships in medical oncology at the National Cancer Institute (NCI) and in clinical pharmacology at the Uniformed Services University in Bethesda. Until 2000, he was a senior investigator in the NCI’s Medicine Branch and an assistant professor at the Uniformed Services University.
In 2000, Dr. Takimoto became an associate professor at the University of Texas Health Science Center at San Antonio (UTHSCSA), and from 2004 to 2007 held the Zachry Chair for Translational Research at the Institute for Drug Development/Cancer Therapy & Research Center. He was also appointed adjunct professor of pharmacology at UTHSCSA. In 2007, he became one of the founding members of South Texas Accelerated Research Therapeutics (START), an independent early phase oncology clinical research center. As a Phase 1 investigator in San Antonio, he was the principal investigator or sub-investigator on approximately 250 early phase oncology clinical trials.
He joined Janssen Pharmaceuticals in 2008 as vice president and head of experimental medicine early development in oncology. He currently serves as chief medical officer at Forty Seven, Inc., an immuno-oncology research organization.
Dr. Takimoto has published over 160 research articles, reviews, editorials and book chapters and has served on the editorial board of numerous oncology publications.